LensAR laser cataract surgery system receives FDA approval for anterior capsulotomy, laser phacofragmentation

LensAR (Orlando, FL) has received FDA approval of its next-generation LensAR Laser System for use in anterior capsulotomy, with and without laser phacofragmentation during cataract surgery. While the company’s first-generation platform had received FDA clearances already, this FDA approval covers the version that is now in final preparation for commercial launch in the U.S.

The system's proprietary technology for 3D imaging measurement and beam-guided delivery generates a personalized surgical treatment plan: Precise measurement of lens tilt and decentration in 3D aligns the treatment plan with the patient’s unique positioning, anatomy, and visual axis. Cataract fragmentation cutting algorithms address all cataract grades, while reducing or eliminating the amount of ultrasound energy required to complete the surgery. Also, the system features a laser head and patient docking system that moves to the patient while accommodating a standard patient gurney.

So far, commercial LensAR Laser Systems have been installed at the Instituto de Ojos Sacro Cuore (Lima, Peru) and the Asian Eye Institute (The Philippines).

-----

Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn

Follow Laser Focus World on your iPhone or Android

Subscribe now to BioOptics World magazine; it's free!